Please login to the form below

Not currently logged in
Email:
Password:

China pharma market

This page shows the latest China pharma market news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda picks up third approval for NSCLC in China

Merck’s Keytruda picks up third approval for NSCLC in China

of non-small cell lung cancer (NSCLC) in China in less than a year. . ... The increasing size and growth of China’s pharma market has made it a significant target for many big Western pharma companies, but the approval of new cancer immunotherapies

Latest news

  • AstraZeneca launches $1bn Chinese investment fund AstraZeneca launches $1bn Chinese investment fund

    As the world’s second-largest healthcare market after the US, China has been a target for many big pharma companies, and AstraZeneca is already among the multinational drug industry’s  ... The announcement of the new investment fund is just one way

  • China first market to approve AZ’s kidney drug roxadustat China first market to approve AZ’s kidney drug roxadustat

    China is an important market for the orally-active drug because it has far more CKD patients than the US – some estimates suggest five times as many. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while Astellas

  • Chi-Med and Lilly’s cancer drug Elunate a milestone for China Chi-Med and Lilly’s cancer drug Elunate a milestone for China

    Chi-Med has achieved a major milestone for itself and China’s fast-developing pharma market, announcing today the launch of cancer treatment Elunate (fruquintinib) in the country. ... However companies like Chi-Med can rely on the sheer scale of

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    China’s pharma market was worth $140bn last year, according to BMI Research, and is predicted to rise 15% to almost $170bn this year thanks to its large and expanding population, ... The size of the market has made it a big target for many big pharma

  • AZ pushes harder into China with new joint venture AZ pushes harder into China with new joint venture

    AstraZeneca has signed another deal to help it unlock the Chinese pharma market, setting up a new joint venture company to bring its drugs to market there more quickly. ... Other investments by AZ in China - now the second-largest pharma market in the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    and a series of sweeping reforms is now opening China’s pharma market to rapid modernisation. ... China is already the world’s second biggest market for pharma, worth $123bn in revenues last year, according to LEK Consulting.

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    Clearly China is a major market for everything. But the number of diabetes patients is growing strongly there. ... Clearly China is a major market for everything, but we see an opportunity there for our diabetes portfolio.

  • Market access opportunities in China Market access opportunities in China

    Pope Woodhead highlights the key steps to accessing the high-value therapeutics market in China. ... long-term strategy to access the market, unlocking regional opportunities for reimbursement in China is viable.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics